Hero Background

US Rabies Diagnostics Market

ID: MRFR/HC/17964-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026
US Rabies Diagnostics Market Research Report: Size, Share, Trend Analysis By Method (Fluorescent Antibody Test (FAT), Immunohistochemical Test, Amplification Methods, Histologic Examination, Serology Tests), By End Users (Hospitals, Diagnostic centers, Cancer Palliative care clinics, Others), By Technology (ELISA/Immunohistochemistry, Chromatography Techniques, PCR, Other), By Region - Forecast to 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Method (USD Million)
      1. 4.1.1 Fluorescent Antibody Test (FAT)
      2. 4.1.2 Immunohistochemical Test
      3. 4.1.3 Amplification Methods
      4. 4.1.4 Histologic Examination
      5. 4.1.5 Serology Tests
    2. 4.2 Construction, BY Technology (USD Million)
      1. 4.2.1 ELISA/Immunohistochemistry
      2. 4.2.2 Chromatography Techniques
      3. 4.2.3 PCR
      4. 4.2.4 Other
    3. 4.3 Construction, BY End User (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Diagnostic centers
      3. 4.3.3 Cancer Palliative care clinics
      4. 4.3.4 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Thermo Fisher Scientific (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Roche Diagnostics (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Abbott Laboratories (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bio-Rad Laboratories (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck KGaA (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 IDEXX Laboratories (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Heska Corporation (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Vetoquinol (FR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Zoetis (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY METHOD
    3. 6.3 US MARKET ANALYSIS BY TECHNOLOGY
    4. 6.4 US MARKET ANALYSIS BY END USER
    5. 6.5 KEY BUYING CRITERIA OF CONSTRUCTION
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF CONSTRUCTION
    8. 6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION
    11. 6.11 CONSTRUCTION, BY METHOD, 2024 (% SHARE)
    12. 6.12 CONSTRUCTION, BY METHOD, 2024 TO 2035 (USD Million)
    13. 6.13 CONSTRUCTION, BY TECHNOLOGY, 2024 (% SHARE)
    14. 6.14 CONSTRUCTION, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    15. 6.15 CONSTRUCTION, BY END USER, 2024 (% SHARE)
    16. 6.16 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY METHOD, 2025-2035 (USD Million)
      2. 7.2.2 BY TECHNOLOGY, 2025-2035 (USD Million)
      3. 7.2.3 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Construction Market Segmentation

Construction By Method (USD Million, 2025-2035)

  • Fluorescent Antibody Test (FAT)
  • Immunohistochemical Test
  • Amplification Methods
  • Histologic Examination
  • Serology Tests

Construction By Technology (USD Million, 2025-2035)

  • ELISA/Immunohistochemistry
  • Chromatography Techniques
  • PCR
  • Other

Construction By End User (USD Million, 2025-2035)

  • Hospitals
  • Diagnostic centers
  • Cancer Palliative care clinics
  • Others